AstraZeneca today announced a $3.5 billion investment in the United States to expand the company’s research and manufacturing footprint by the end of 2026. This includes $2 billion in new investments creating more than 1,000 new high-skilled jobs that will…
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the close of an oversubscribed $84…
Reverb Therapeutics, a leader harnessing the body’s immune system and cytokine signaling to treat life-threatening diseases, announced it has launched a collaboration with Royalmount Laboratories, based in Montreal, as Reverb works towards lead selection and pre-IND enabling work on its…
Baxter International Inc. (NYSE: BAX), a global leader in medical technology, today announced its financial results for the third quarter of 2024. “Baxter achieved strong performance in Q3 2024 as we continue to execute on our strategic transformation,” said José…
Royalty Pharma plc (Nasdaq: RPRX) announced an agreement to acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO, with a $125 million upfront cash payment. Approved by the U.S. FDA in June 2024, RYTELO is a…
WuXi Biologics (“WuXi Bio”) (2269.HK), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings for the second consecutive year. This prestigious recognition acknowledges the…
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company developing transformative gene-based medicines for serious diseases, has released its financial results for Q3 ending September 30, 2024. “We are making strong progress across our pipeline of in vivo and ex vivo CRISPR-based…
Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) have announced a $350 million synthetic royalty funding agreement, tied to the U.S. net sales of Niktimvo (axatilimab-csfr). “We are thrilled to partner with Syndax, a forward-thinking oncology company with…
BioNTech SE (Nasdaq: BNTX) has announced its financial results for the third quarter and the first nine months of 2024, alongside updates on its corporate initiatives. During this period, the company successfully launched its variant-adapted COVID-19 vaccines and advanced its…
Vir Biotechnology, Inc. (Nasdaq: VIR) has released its corporate update and financial results for the third quarter ended September 30, 2024. “This quarter marked a transformative period for Vir. We have strengthened our clinical pipeline with three promising dual-masked T-cell…
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Toichi Takino; “the Company”) today announced that it has revised its consolidated financial forecasts for the full-year period ending March 2025 disclosed at the announcement of financial results ended March 2024, made on…
Global healthcare company Viatris has been named to Forbes’ World’s Top Companies for Women 2024 list, an honor awarded in collaboration with Statista, a leading statistics and industry ranking provider. “At Viatris, diverse perspectives fuel innovation and our mission to…